(Q81282674)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15654549%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

title

Comparative tolerance of IFN beta-1a regimens in patients with relapsing multiple sclerosis. The EVIDENCE study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15654549%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

author name string

M Sandberg-Wollheim

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15654549%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

C Bever

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15654549%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

J Carter

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15654549%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

M Färkkilä

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15654549%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

B Hurwitz

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15654549%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Y Lapierre

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15654549%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

P Chang

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15654549%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

G S Francis

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15654549%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

EVIDENCE Study Group

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15654549%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

publication date

1 January 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15654549%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15654549%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

volume

252

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15654549%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15654549%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

page(s)

8-13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15654549%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00415-005-0589-2

7 January 2020

exact match

0 references

cites work

Comparative pharmacokinetics and pharmacodynamics of two recombinant human interferon beta-1a (IFN beta-1 a) products administered intramuscularly in healthy male and female volunteers

1 reference

12 December 2020

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

12 December 2020

A comparison of the biologic activity of two recombinant IFN-beta preparations used in the treatment of relapsing-remitting multiple sclerosis.

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial

1 reference

12 December 2020

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

1 reference

12 December 2020

A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS

1 reference

12 December 2020

Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance

1 reference

12 December 2020

Pharmacodynamic comparison of single doses of IFN-beta1a and IFN-beta1b in healthy volunteers.

1 reference

12 December 2020

Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group

1 reference

12 December 2020

Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in

1 reference

12 December 2020

Influence of interferon beta-1a dose frequency on PBMC cytokine secretion and biological effect markers

1 reference

12 December 2020

Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020